ESTRACYT

This brand name is authorized in Estonia, France, Japan, Netherlands, Singapore, Spain, Turkey, UK.

Active ingredients

The drug ESTRACYT contains one active pharmaceutical ingredient (API):

1	Estramustine phosphate sodium UNII MUZ9585Y7B - ESTRAMUSTINE PHOSPHATE
	Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect.
	Read more about Estramustine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ESTRACYT Capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX11	Estramustine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1021161, 1778935
ES	Centro de información online de medicamentos de la AEMPS	54190
FR	Base de données publique des médicaments	60675618
GB	Medicines & Healthcare Products Regulatory Agency	39652
JP	医薬品医療機器総合機構	4219003M1054
NL	Z-Index G-Standaard, PRK	2518
SG	Health Sciences Authority	09464P
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308151018